LigaChem Biosciences (141080 KQ/Buy)Clinical Data to Watch in 2026
We valued LCB14 (HER2-targeting ADC; regulatory filing in China expected in 2026) at W1.47tr and LCB84 (Trop2-targeting ADC; phase 1 trials to be...
379 Views
[2H26 Outlook] Pharma/BiotechCatalysts for a biotech rebound
Biotech stocks performed well early this year, driven by optimism surrounding the government's KOSDAQ 3,000 target and supportive fund flows...
119 Views